Latest News

ODAC Votes Against Risk-Benefit Profile of GSK’s Blenrep Combinations in Relapsed/Refractory Multiple Myeloma
ODAC Votes Against Risk-Benefit Profile of GSK’s Blenrep Combinations in Relapsed/Refractory Multiple Myeloma

July 18th 2025

Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and highlights global momentum behind Blenrep combination approvals.

Obsolete Trial Marketing Guidelines and Missing Processes Hurt Patient Enrollment
Obsolete Trial Marketing Guidelines and Missing Processes Hurt Patient Enrollment

July 8th 2025

Funding Cuts Threaten Diversity in Clinical Research
Funding Cuts Threaten Diversity in Clinical Research

June 27th 2025

© putilov_denis - © putilov_denis - stock.adobe.com
Tokenization: The Unsexy Plumbing of Clinical Research

June 24th 2025

Credit: Tada Images | stock.adobe.com
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies

June 18th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.